Procept BioRobotics Corporation (PRCT)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.4 per share a year ago.
Earnings Preview: PROCEPT BioRobotics Corporation (PRCT) Q3 Earnings Expected to Decline
PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Procept BioRobotics: A Strong Challenger Positioned To Be A Future Leader
PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indications, and international momentum support margin expansion, scalability, and long-term growth in its niche market. Valuation is attractive at current levels, with a DCF-derived target price of $50.9 and profitability expected by the end of 2027, offering an attractive accumulation opportunity.
Procept BioRobotics Corporation (PRCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Procept BioRobotics Corporation ever had a stock split?
Procept BioRobotics Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Larry L. Wood CEO | NASDAQ (NMS) Exchange | 74276L105 CUSIP |
| US Country | 756 Employees | - Last Dividend | - Last Split | 15 Sep 2021 IPO Date |
Overview
PROCEPT BioRobotics Corporation is a pioneering entity within the surgical robotics landscape, concentrating its efforts on spearheading innovative solutions within the field of urology, both domestically within the United States and across the global front. Established in 2007, with its headquarters situated in San Jose, California, the company dedicates itself to addressing the complex needs of urologic surgery. Its mission revolves around enhancing patient care by providing advanced, minimally invasive surgical options, specifically targeting benign prostatic hyperplasia (BPH), a common urological condition. Through its commitment to innovation and technology, PROCEPT BioRobotics aspires to redefine urologic surgery and improve patient outcomes on a worldwide scale.
Products and Services
The AquaBeam Robotic System - This flagship product represents a forefront innovation in the domain of surgical robotics, specifically engineered for use in minimally invasive urologic surgery. The system is designed with precision in mind, employing image-guidance to ensure accuracy during procedures. Its primary application is in the treatment of benign prostatic hyperplasia (BPH), offering a promising option for patients seeking less invasive treatment modalities. The system illustrates PROCEPT BioRobotics Corporation's commitment to advancing medical technology and improving surgical outcomes.
Aquablation Therapy - A complementary therapy designed by PROCEPT BioRobotics, Aquablation therapy stands as a testament to the company's focus on male urologic wellness, particularly for those experiencing lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The therapy utilizes the meticulous application of waterjet technology, controlled by the groundbreaking AquaBeam Robotic System, to remove prostate tissue and alleviate symptoms. This innovative approach reflects the company's dedication to providing solutions that enhance the quality of life for patients enduring BPH.
Contact Information
